GoAI
Get started
Scilex Holding Company logo

Scilex Holding Company

SCLX

NASDAQHealthcareDrug Manufacturers - General

Open in GoAI

Previous close

$5.73

−$0.07 · -1.21%

Aug 21, 4:00 PM ET

Pre-market

$5.62

−$0.11 · -1.92%

Aug 24, 7:59 AM ET

SCLX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

38

Expensive

Momentum

51

Neutral

Sentiment

55

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
US
CEO
Henry H. Ji
Listed since
Mar 5, 2021
Employees
34

Market position

Day range

Current $5.73

52-week range

Current $5.73

Open
$5.81
Previous close
$5.80
Volume
26.02K
0.2× average
Average volume
127.45K
Average daily volume
Market cap
48.65M USD
Beta
1.74
Market reference 1
50-day average
$7.2017
-20.44% below average
200-day average
$6.8164
-15.94% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-12.83
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends216%-294%-804%-1313%Gross margin, FY2021: 88.40%Gross margin, FY2022: 71.61%Gross margin, FY2023: 66.45%Gross margin, FY2024: 70.51%Gross margin, FY2025: 49.68%Operating margin, FY2021: -114.44%Operating margin, FY2022: -133.13%Operating margin, FY2023: -225.55%Operating margin, FY2024: -147.37%Operating margin, FY2025: -900.09%Net margin, FY2021: -282.35%Net margin, FY2022: -61.43%Net margin, FY2023: -244.59%Net margin, FY2024: -128.66%Net margin, FY2025: -1185.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 88.40%. Gross margin FY2022 71.61%. Gross margin FY2023 66.45%. Gross margin FY2024 70.51%. Gross margin FY2025 49.68%. Operating margin FY2021 -114.44%. Operating margin FY2022 -133.13%. Operating margin FY2023 -225.55%. Operating margin FY2024 -147.37%. Operating margin FY2025 -900.09%. Net margin FY2021 -282.35%. Net margin FY2022 -61.43%. Net margin FY2023 -244.59%. Net margin FY2024 -128.66%. Net margin FY2025 -1185.78%.

Income trends

Revenue

30.25M USD-46.54%

Operating income

−272.3M USD-226.52%

Net income

−358.73M USD-392.72%
Income trends across reported periods98.12M USD−68.01M USD−234.14M USD−400.27M USDRevenue, FY2021: 31.32M USDRevenue, FY2022: 38.03M USDRevenue, FY2023: 46.74M USDRevenue, FY2024: 56.59M USDRevenue, FY2025: 30.25M USDOperating income, FY2021: −35.84M USDOperating income, FY2022: −50.63M USDOperating income, FY2023: −105.43M USDOperating income, FY2024: −83.4M USDOperating income, FY2025: −272.3M USDNet income, FY2021: −88.42M USDNet income, FY2022: −23.36M USDNet income, FY2023: −114.33M USDNet income, FY2024: −72.81M USDNet income, FY2025: −358.73M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 31.32M USD. Revenue FY2022 38.03M USD. Revenue FY2023 46.74M USD. Revenue FY2024 56.59M USD. Revenue FY2025 30.25M USD. Operating income FY2021 −35.84M USD. Operating income FY2022 −50.63M USD. Operating income FY2023 −105.43M USD. Operating income FY2024 −83.4M USD. Operating income FY2025 −272.3M USD. Net income FY2021 −88.42M USD. Net income FY2022 −23.36M USD. Net income FY2023 −114.33M USD. Net income FY2024 −72.81M USD. Net income FY2025 −358.73M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue30.25M USD56.59M USD46.74M USD38.03M USD31.32M USD
Cost of goods sold15.22M USD16.69M USD15.68M USD10.8M USD3.63M USD
Gross profit15.03M USD39.9M USD31.06M USD27.24M USD27.68M USD
Research and development20.71M USD9.64M USD12.75M USD9.05M USD9.2M USD
Selling, general, and administrative266.63M USD119.02M USD119.64M USD64.9M USD50.58M USD
Operating expenses287.34M USD123.3M USD136.49M USD77.87M USD63.52M USD
Interest expense11.46M USD1.96M USD1.07M USD9.6M USD11.76M USD
Depreciation and amortization4.62M USD4.05M USD4.15M USD4.45M USD3.78M USD
Operating income−272.3M USD−83.4M USD−105.43M USD−50.63M USD−35.84M USD
Net income−358.73M USD−72.81M USD−114.33M USD−23.36M USD−88.42M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 8 misses, 1 met estimate
Average EPS surprise
-1418.22%
11 comparable reports
Latest EPS result
-16.65
Estimate -0.18 · Miss by 9083.17%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.02-6.01-11.99-17.98Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MetQ2 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.023, estimate -0.1, surprise +77.40%, Beat. Q2 2025, reported May 14, 2025: actual -2.26, estimate -4.2, surprise +46.19%, Beat. Q3 2025, reported Aug 12, 2025: actual -4.62, estimate -0.567, surprise -715.39%, Miss. Q4 2025, reported Nov 14, 2025: actual -13.8, estimate -13.8, surprise 0.00%, Met estimate. Q2 2026, reported Apr 10, 2026: actual -4.6, estimate -0.293, surprise -1471.90%, Miss. Q2 2026, reported May 20, 2026: actual -4.76, estimate -0.21, surprise -2166.45%, Miss. Q3 2026, reported Aug 14, 2026: actual -16.65, estimate -0.181, surprise -9083.17%, Miss. Q4 2026, reported Dec 2, 2026: actual —, estimate -0.076, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates27.97M20M12.04M4.07MQ1 '25MissQ2 '25MetQ3 '25MissQ4 '25MetQ2 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 14.9M USD, estimate 17.79M USD, surprise -16.24%, Miss. Q2 2025, reported May 14, 2025: actual 5M USD, estimate 5M USD, surprise 0.00%, Met estimate. Q3 2025, reported Aug 12, 2025: actual 9.9M USD, estimate 26.25M USD, surprise -62.30%, Miss. Q4 2025, reported Nov 14, 2025: actual 10.56M USD, estimate 10.56M USD, surprise 0.00%, Met estimate. Q2 2026, reported Apr 10, 2026: actual 4.79M USD, estimate 12.1M USD, surprise -60.39%, Miss. Q2 2026, reported May 20, 2026: actual 8.61M USD, estimate 15M USD, surprise -42.58%, Miss. Q3 2026, reported Aug 14, 2026: actual 7.64M USD, estimate 16M USD, surprise -52.24%, Miss. Q4 2026, reported Dec 2, 2026: actual —, estimate 17M USD, surprise —, Comparison unavailable.

SCLX news

globenewswire.com

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and…

Read source
globenewswire.com

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing…

Read source
globenewswire.com

Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing…

Read source
gurufocus.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation

Read source
prnewswire.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the…

Read source
globenewswire.com

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 15, 2025

1:35

SCLX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SCLX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.45M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
508.07K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
138.82K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis Total Equity Markets ETF 1 logoAvantis Total Equity Markets ETF 1AVTM
Market value
464
Weight
—
AUM
795.5M USD
Expense ratio
0.23%
Price / 1D
$55.32020.00%
Dimensional - US Core Equity Market ETF logoDimensional - US Core Equity Market ETFDFAU
Market value
378.18
Weight
0.00%
AUM
12.79B USD
Expense ratio
0.12%
Price / 1D
$53.06+0.44%

Continue in GoAI

Research SCLX

research.disclaimer